Mercer Global Advisors’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$540K Buy
51,765
+2,611
+5% +$28.9K ﹤0.01% 2386
2026
Q2
$506K Buy
+49,154
New +$371K ﹤0.01% 2285

Other funds holding CADL

Mercer Global Advisors's CADL Position: Q3 2026 in Review

Mercer Global Advisors increased its Candel Therapeutics (CADL) stake by 5.3% in Q3 2026, buying an estimated $28.9K and bringing the position to 51,765 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

Mercer Global Advisors first reported a position in CADL in Q2 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Mercer Global Advisors held 51,765 shares of Candel Therapeutics worth $540K as of Q3 2026.
  • Mercer Global Advisors bought 2,611 Candel Therapeutics shares in Q3 2026, an estimated $28.9K.
  • Candel Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #2386 holding.
  • Mercer Global Advisors first reported a position in Candel Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.